The invention relates to a preparation method of (4-isopropoxy-2-methyl)phenyl isopropyl ketone, particularly the preparation method includes: reacting m-cresol with thiocyanate in the presence of a catalyst to obtain a product A; reacting the product A with haloisopropane in the presence of a base and a catalyst to obtain a product B; reacting the product B with isopropyl magnesium halide and treating to obtain (4-isopropoxy-2-methyl)phenyl isopropyl ketone. The purity of (4-isopropoxy-2-methyl)phenyl isopropyl ketone prepared is more than 99%, and the total yield is more than 79%. The method according to the present invention avoids the use of toxic reagents and the generation of a large amount of acidic wastewater, reduces the reaction temperature, and improves the reaction yield. The process route is simple and efficient, and the cost is reduced. The purity of the resulting product is high, the production security is greatly improved, and the method is easy to industrialize.

The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.10 and R.sup.11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP.sub.4 receptors.

##STR00001##

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation. ##STR00001##

The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I):

##STR00001##

or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q.sub.1, Q.sub.2, Z, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

The present application relates to a curable composition. The present application provides a curable composition comprising an internal heat source for generating heat by application of an alternate-current magnetic field from the outside, together with a phthalonitrile compound and a curing agent therefor. The curable composition can precisely control the heat generated from the internal heat source according to the strength of the alternate-current magnetic field to precisely control curing conditions of the curable composition.

The present application relates to a curable composition. The present application provides a curable composition comprising an internal heat source for generating heat by application of an alternate-current magnetic field from the outside, together with a phthalonitrile compound and a curing agent therefor. The curable composition can precisely control the heat generated from the internal heat source according to the strength of the alternate-current magnetic field to precisely control curing conditions of the curable composition.

An organic compound is represented by formula (1). In the formula (1), R.sub.1 to R.sub.24 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryloxy group, a silyl group, and a cyano group. ##STR00001##